Can Aurinia Pharmaceuticals cover its short-term obligations?

Its current ratio is 5.55 — current assets exceed current liabilities.

Where does Aurinia Pharmaceuticals's balance sheet data come from?

Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Aurinia Pharmaceuticals AUPH Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$80.21M-3.9%	$83.43M+70.7%	$48.88M-48.1%	$94.17M-59.4%
Restricted cash	——	——	——	$100K-66.7%
Accounts receivable, net	$41.45M+13.4%	$36.54M+51.7%	$24.09M+78.7%	$13.48M-12.5%
Inventories	$183.18M+17.0%	$156.56M+13.9%	$137.43M+34.5%	$102.2M+42.1%
Raw materials	$658K-61.3%	$1.7M-2.5%	$1.75M-21.2%	$2.22M0.0%
Work in process	$44.65M+21.9%	$36.62M-2.0%	$37.38M+77.5%	$21.06M+67.6%
Finished goods	$379K-58.0%	$903K+12.9%	$800K-79.5%	$3.9M-14.2%
Prepaid expenses and other current assets	$3.13M-28.8%	$4.39M+326%	$1.03M-92.4%	$13.58M+8.6%
Total current assets	$491.97M+10.2%	$446.6M+5.1%	$424.8M-4.0%	$442.54M-13.8%
Property and equipment, net	$2.11M-22.7%	$2.73M-18.6%	$3.35M-8.1%	$3.65M-17.4%
Accumulated depreciation	$3.15M+24.5%	$2.53M+32.6%	$1.91M+31.3%	$1.46M+74.0%
Operating lease right-of-use assets	$3.6M-11.6%	$4.07M-9.6%	$4.5M-8.3%	$4.91M-8.8%
Intangible assets, net	$3.76M-13.6%	$4.36M-12.5%	$4.98M-22.5%	$6.43M-23.5%
Deferred tax assets	——	$0—	$0—	——
Other non-current assets	$93K-88.7%	$823K-45.7%	$1.52M-88.6%	$13.34M+12.7%
Allowance for credit losses	$397.79M+11.0%	$358.32M+2.3%	$350.42M—	——
Total assets	$751.59M+36.5%	$550.65M+0.5%	$548.06M+16.4%	$470.86M-13.3%
Accounts payable	$3.31M-36.1%	$5.19M+19.9%	$4.33M+40.2%	$3.09M-20.4%
Accrued expenses	$18.87M+1,132%	$1.53M-35.9%	$2.39M+17.5%	$2.03M-54.3%
Deferred revenue	$3.72M-66.2%	$11M+129%	$4.81M+52.9%	$3.15M+1,557%
Current portion of long-term debt	$16.52M+17.6%	$14.05M-3.9%	$14.61M—	$0—
Operating lease liabilities, current	$1.07M+4.0%	$1.03M+3.7%	$989K+5.7%	$936K-11.6%
Finance Lease Liability, Current	$16.52M+17.6%	$14.05M-3.9%	$14.61M—	$0—
Contract liabilities	$12.65M+644%	$1.7M—	——	——
Income taxes payable	$2.01M+300%	$503K-24.6%	$667K+6.7%	$625K-23.2%
Accrued interest	$700K+16.7%	$600K-14.3%	$700K-36.4%	$1.1M+1,000%
Total current liabilities	$93.72M-4.1%	$97.76M+26.7%	$77.19M+67.4%	$46.11M+13.4%
Operating lease liabilities, non-current	$4.9M-14.7%	$5.74M-12.1%	$6.53M-8.7%	$7.15M-6.9%
Finance Lease Liabilities (Total)	$68.85M-5.2%	$72.6M-19.4%	$90.09M—	——
Operating Lease Liabilities (Total)	$5.97M-11.8%	$6.77M-10.0%	$7.52M-7.0%	$8.09M-7.4%
Finance lease liabilities	$52.32M-10.6%	$58.55M-22.4%	$75.48M—	$0—
Other non-current liabilities	$6.7M-28.7%	$9.4M-13.8%	$10.91M-10.3%	$12.17M-23.7%
Total liabilities	$170.26M-1.7%	$173.17M+1.8%	$170.11M+160%	$65.43M+1.8%
Common stock	$1.12B-5.7%	$1.19B-1.0%	$1.2B+1.3%	$1.19B+0.7%
Additional paid-in capital	$111.26M-12.4%	$127M+5.1%	$120.79M+41.3%	$85.49M+44.9%
Retained earnings	-$649.37M+30.7%	-$936.57M+0.6%	-$942.32M-9.0%	-$864.3M-14.3%
Accumulated other comprehensive income (loss)	-$599K+7.4%	-$647K+11.4%	-$730K+31.2%	-$1.06M-24.5%
Total stockholders' equity	$581.33M+54.0%	$377.48M-0.1%	$377.95M-6.8%	$405.44M-15.4%
Total liabilities and stockholders' equity	$751.59M+36.5%	$550.65M+0.5%	$548.06M+16.4%	$470.86M-13.3%
Finished goods	$379K-58.0%	$903K+54.9%	$583K-60.5%	$1.48M-67.5%
Other current assets	$1.08M-4.3%	$1.13M+9.5%	$1.03M-22.7%	$1.33M+67.6%
Prepaid expenses and deposits	$5.75M-48.8%	$11.22M+18.3%	$9.49M—	——
Deferred Tax Assets and Other Non-Current Assets	$93K-88.7%	$823K-45.7%	$1.52M-88.6%	$13.34M+12.7%
Finite Lived Intangible Assets - Gross	$20.38M+1.3%	$20.13M+1.4%	$19.85M+1.4%	$19.57M+0.5%
Net Investment in Lease	$3.6M-11.6%	$4.07M-9.6%	$4.5M-8.3%	$4.91M-8.8%
Deferred tax assets	$176.19M—	$0—	——	——
Intangible assets — net	$3.76M-13.6%	$4.36M-12.5%	$4.98M-22.5%	$6.43M-23.5%
Operating lease right-of-use assets	$3.6M-11.6%	$4.07M-9.6%	$4.5M-8.3%	$4.91M-8.8%
Other non-current assets	$93K-88.7%	$823K-45.7%	$1.52M-88.6%	$13.34M+12.7%
Property, plant and equipment at cost	$5.26M0.0%	$5.26M0.0%	$5.26M+3.1%	$5.11M-2.8%
Operating Lease Right-of-Use Assets in Other Assets	$3.6M-11.6%	$4.07M-9.6%	$4.5M-8.3%	$4.91M-8.8%
Software and Technology Licenses, Net	$93K-88.7%	$823K-45.7%	$1.52M-88.6%	$13.34M+12.7%
Accrued Manufacturing Costs	$18.87M+1.2%	$18.64M-17.1%	$22.49M+11.2%	$20.21M+10.6%
Accrued Marketing and Advertising Expenses	$1.65M-29.2%	$2.33M—	——	——
Accrued Progress Collections and Price Adjustments	$12.65M+644%	$1.7M—	——	——
Other Commercial Liabilities	$66.62M+2.5%	$64.97M+29.8%	$50.06M—	——
Accounts payable and other current liabilities (Note 11)	$66.62M+2.5%	$64.97M+19.5%	$54.39M+36.0%	$39.99M+14.4%
Accrued Liabilities, Current	$66.62M+2.5%	$64.97M+29.8%	$50.06M—	——
Compensation and benefits	$18.87M+1.2%	$18.64M-17.1%	$22.49M+11.2%	$20.21M+10.6%
Other accrued liabilities	$2.48M+62.0%	$1.53M-35.9%	$2.39M+17.5%	$2.03M-54.3%
Finance Lease Liability Payment Due	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Contract Liabilities, Non-Current	$12.65M+644%	$1.7M—	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Marketing and selling	$1.65M-29.2%	$2.33M—	——	——
Deferred revenue, net of current portion	$12.65M+644%	$1.7M—	——	——
Deferred income	$12.65M+644%	$1.7M—	——	——
Total debt	$91.34M-2.2%	$93.42M-16.8%	$112.22M+1,287%	$8.09M-7.4%
Common Stock Par Value Per Share	$0.00—	$0.00—	$0.00—	$0.00—
Common Stock Shares Issued	132.3M-6.1%	140.9M-2.1%	143.8M+1.1%	142.3M+0.5%
Additional paid-in capital	$111.26M-12.4%	$127M+5.1%	$120.79M+41.3%	$85.49M+44.9%
Share-Based Payment Award Options Outstanding - Number	9M-3.1%	9.3M-19.7%	11.6M-13.1%	13.3M+10.1%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$9.98-9.3%	$11.00+3.5%	$10.63-12.1%	$12.09-5.8%
Cumulative Cost Basis	$5.26M0.0%	$5.26M0.0%	$5.26M+3.1%	$5.11M-2.8%
Accrued research and development expenses	$6.13M+53.6%	$3.99M—	——	——
Accrued sales rebates and fees	$30.83M+25.5%	$24.57M—	——	——
Total cash, cash equivalents, restricted cash and short-term investments	$398M+11.0%	$358.48M+2.3%	$350.49M-10.0%	$389.4M-16.5%
Common stock, par value (in dollars per share)	$0—	$0—	$0—	$0—
Common stock, shares issued (in shares)	$132.32M-6.1%	$140.88M-2.1%	$143.83M+1.1%	$142.27M+0.5%
Common Stock, Shares, Outstanding	$132.32M-6.1%	$140.88M-2.1%	$143.83M+1.1%	$142.27M+0.5%
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$397.79M+11.0%	$358.32M+2.3%	$350.42M—	——
Debt Securities, Current	$317.78M+15.5%	$275.04M-8.8%	$301.61M+2.2%	$295.22M+26.1%
Deferred compensation and other noncurrent liabilities	$6.66M-29.2%	$9.41M—	——	——
Cost not yet recognized	——	——	——	——
Current maturities of long-term debt	$16.52M+17.6%	$14.05M-3.9%	$14.61M—	$0—
Finance Lease Liability Payments Due	——	——	——	——
2027	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$73.87M-19.8%	$92.07M-15.3%	$108.72M—	$0—
Finite-Lived Intangible Assets, Accumulated Amortization	$16.62M+5.4%	$15.77M+6.1%	$14.87M+13.1%	$13.14M+18.8%
Gross Carrying Amount	$20.38M+1.3%	$20.13M+1.4%	$19.85M+1.4%	$19.57M+0.5%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Other accrued liabilities	$7.14M+74.6%	$4.09M-21.3%	$5.19M+148%	$2.09M-40.6%
Prepaid Insurance	$878K-26.0%	$1.19M-5.0%	$1.25M-30.6%	$1.8M+10.2%
Prepaid manufacturing and other deposits	$1.74M-69.1%	$5.65M—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$8.99M-3.1%	$9.28M-19.7%	$11.56M-13.1%	$13.3M+10.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$9.98-9.3%	$11+3.5%	$10.63-12.1%	$12.09-5.8%
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Aurinia Pharmaceuticals cover its short-term obligations?: Its current ratio is 5.55 — current assets exceed current liabilities.
Where does Aurinia Pharmaceuticals's balance sheet data come from?: Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.